気分障害がない方が糖尿病性性神経障害にサインバルタが有効


方法:COMBO-DN研究のデータに基づき, DPNPの多国家研究を行い, the potential impact of baseline characteristics on pain relief after 8-week monotherapy with 60 mg/day duloxetine 又は300 mg/day pregabalinの8週間の単独治療の鎮痛に影響する治療前の特徴を、共変量の解析を用いて評価。 治療前の特徴と効果によりサブグループ化。結果:804人を評価。治療は気分症状と有意な関連があり、duloxetineで治療した患者で大きく痛みが軽減した患者は気分症状がなかった[Hospital Anxiety and Depression Scale (HADS) 抑うつ又は不安サブスケール点数<11; -2.33 (duloxetine); -1.52 (pregabalin); p = 0.024].年齢(<65 or ≥65 歳), 性別, 治療開始時の痛みの強さ[Brief Pain Inventory Modified Short Form (BPI-MSF) average pain <6 or ≥6], 糖尿病性神経障害の期間(≤2 or >2 年), 治療開始時のHbA1c(<8% or ≥8%), 合併症の存在と併用薬の使用のサブグループと治療には有意な関連はなかった。
Eur J Pain. 2015 Aug 27. doi: 10.1002/ejp.763. [Epub ahead of print]
Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
Marchettini P1,2, Wilhelm S3, Petto H4, Tesfaye S5, Tölle T6, Bouhassira D7, Freynhagen R8,9, Cruccu G10, Lledó A11, Choy E12, Kosek E13, Micó JA14, Späth M15, Skljarevski V16, Lenox-Smith A17, Perrot S18.
•1Pain Medicine Center, Department of Neurology, Hospital San Raffaele, Milano, Italy.
•2Pain Pathophysiology and Therapy, University of Southern Switzerland, Manno, Switzerland.
•3Regional Medical Affairs, Lilly Deutschland GmbH, Bad Homburg, Germany.
•4Global Statistical Sciences, Lilly Austria, Vienna, Austria.
•5Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, UK.
•6Neurologische Klinik und Poliklinik, Technische Universität, München, Germany.
•7INSERM U987 Centre d'Evaluation et de Traitement de la Douleur, Hôpital Ambroise Paré, Boulogne Billancourt, France.
•8Zentrum für Anästhesiologie, Intensivmedizin, Schmerztherapie & Palliativmedizin, Benedictus Krankenhaus, Tutzing.
•9Klinik für Anästhesiologie, Technische Universität München, Germany.
•10Department of Neurology & Psychiatry, Sapienza University, Roma, Italy.
•11Departamento de Neurología, Clínica Creu Blanca, Barcelona, Spain.
•12Section of Rheumatology, Institute of Infection & Immunity, Cardiff University, UK.
•13Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
•14Department of Neuroscience, CIBER of Mental Health, CIBERSAM, University of Cádiz, Spain.
•15Spital Linth, Rheumatologie, Uznach, Switzerland.
•16Lilly Research Laboratories, Indianapolis, USA.
•17Medical Affairs, Eli Lilly & Company, Basingstoke, UK.
•18INSERM U-987 Centre de la Douleur, Hôpital Hotel Dieu, Université Paris Descartes, Paris, France.
[PR]

by fibromyalgia11 | 2015-08-30 13:13 | 抗うつ薬
line

世界標準の線維筋痛症を専門家が説明します


by fibromyalgia11
line